Cell Genesys Inc. (CEGE)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
500 Forbes BoulevardSouth San Francisco, CA 94080
Company Description
Cell Genesys is a biotechnology company that engages in the development and commercialization of biological therapies for patients with cancer. It develops cell-based cancer immunotherapies and oncolytic virus therapies.
Website: http://www.cellgenesys.com
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| GVAX vaccine | immunotherapy | Leukemia | II | Takeda |
| GVAX vaccine | immunotherapy | Pancreatic cancer | II | Takeda |
| CG0070 | oncolytic virus | Bladder cancer | I | Novartis AG |
| GVAX vaccine | immunotherapy | Non Small Cell Lung Cancer (NSCLC) | Preclinical | Takeda |
View additional information on product candidates here »
Recent News Headlines
(Reuters) September 3, 2010 - Celldex Therapeutics Inc said its partner Pfizer ended the deal to co-develop Celldex's cancer vaccine, its lead product, as the program was no longer a strategic priority for the drug giant.
(Los Angeles Times) August 31, 2010 - The Obama administration on Tuesday asked a federal judge to lift a restraining order that it says could undercut U.S. government funded embryonic stem cell research.
(Oregon State University) August 30, 2010 - New research on how skin cancer begins has identified adjacent cancer cells that scientists are calling “co-conspirators” in the genesis of melanoma, in findings that could someday hold the key to predicting, preventing and stopping this hard-to-treat cancer before it spreads.
(AACR) August 25, 2010 - The American Association for Cancer Research (AACR), the world's oldest and largest cancer research organization, reiterates its support for the responsible conduct of human embryonic stem cell research that, up until this week, was funded by the National Institutes of Health (NIH) and expresses concern that the recent Federal District Court injunction to block federal funding for human embryonic stem cell research is a setback for scientific discovery.
(Mayo Clinic) August 24, 2010 - To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer.
(Los Angeles Times) August 24, 2010 - A federal judge blocks U.S. funding for all projects involving the use of material from human embryos.
(ASH) August 18, 2010 - Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology.
(AACR) August 18, 2010 - The American Association for Cancer Research is currently accepting nominations for awards recognizing excellence in cancer research, to be presented at the 102nd AACR Annual Meeting 2011, held in Orlando, Fla., from April 2 to 6.
(ScienceBlog) August 17, 2010 - Adult stem cells that are vital for airway repair in the lung but that persist in areas where pre-cancerous lesions are found are associated with a poor prognosis in patients who develop cancer, even those with early stage disease, researchers at UCLA’s Jonsson Comprehensive Cancer Center have found.
(HHMI) August 15, 2010 - Therapeutic cells, such as those implanted in the body to battle cancer or replenish devastated populations of stem cells, may someday be able to carry their own life-support packets.
(BioCancell) August 15, 2010 - BioCancell Therapeutics Inc. today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to BioCancell's lead drug-candidate, BC-819 (currently in clinical trial stages), for use in treating pancreatic cancer.
(Yahoo! Finance) August 16, 2010 - Cell Therapeutics, Inc. announced today that it has received notice that the European Medicines Agency has validated the expanded Pediatric Investigation Plan that CTI filed in July for pixantrone for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).
(ScienceBlog) August 12, 2010 - A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer.
(ABC News) August 11, 2010 - Treating tumors with salmonella bacteria can induce an immune response that kills cancer cells, scientists have found -- a discovery that may help them create tumor-killing immune cells to inject into patients.
(Reuters) August 12, 2010 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma (RCC).
(UCLA) August 9, 2010 - Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field.
(ScienceBlog) August 3, 2010 - New technologies for the diagnosis of cancer are rapidly changing the clinical practice of oncology. As scientists learn more about the molecular basis of cancer, the development of new tools capable of multiple, inexpensive biomarker measurements on small samples of clinical tissue will become essential to the success of genetically informed and personalized cancer therapies.
(Cell Therapeutics, Inc.) August 4, 2010 - Cell Therapeutics, Inc. today announced it has filed for a Special Protocol Assessment with the U.S. Food and Drug Administration for the design of its new phase III trial of pixantrone for patients with relapsed or refractory aggressive B-Cell non-Hodgkin's lymphoma.
(MarketWatch) August 3, 2010 - ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC).
(Reuters) August 2, 2010 - Pancreatic tumor cells use fructose to divide and proliferate, U.S. researchers said on Monday in a study that challenges the common wisdom that all sugars are the same.
(UCLA Jonsson CCCC) July 29, 2010 - UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of more effective targeted treatments for the disease.
(Yahoo! Finance) July 29, 2010 - Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE® (bortezomib) in patients with relapsed/refractory mantle cell lymphoma (MCL).
(UNC) July 27, 2010 - A normally benign protein found in the human body appears to be able – when paired with nanoparticles – to zero in on and kill certain cancer cells, without having to also load those particles with chemotherapy drugs.
(ACCC) July 27, 2010 - On July 27, 2010, the Association of Community Cancer Centers (ACCC) submitted comments to the Centers for Medicare & Medicaid Services’ (CMS) about the opening of a national coverage analysis (NCA) for autologous cellular immunotherapy of treatment of metastatic prostate cancer.
(MD Anderson) July 22, 2010 - A novel approach detects genetically abnormal cells in the blood of non-small cell lung cancer patients that match abnormalities found in tumor cells and increase in number with the severity of the disease, a research team led by scientists at The University of Texas MD Anderson Cancer Center report in the journal Clinical Cancer Research.
BioSante Pharmaceuticals said Thursday that its GVAX cancer treatment led to a reduction of cancer cells in leukemia patients who had been taking the cancer drug Gleevec for at least one year.
BioSante Pharmaceuticals Inc. said Wednesday that it completed an all-stock buyout of Cell Genesys Inc. and the combined company will focus on developing a topical testosterone gel intended to treat sexual dysfunction in women.
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today announced that BioSante stockholders have approved the merger between the two companies with BioSante as the surviving company.
BioSante Pharmaceuticals Inc. said it is adjusting its exchange ratio with Cell Genesys Inc. as the companies prepare to complete their all-stock tie up.
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today announced that they have determined the final exchange ratio as 0.1828 in connection with the previously announced merger between the companies.
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies.
Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease.
SOUTH SAN FRANCISCO, Calif.----Cell Genesys, Inc. today reported financial results for the second quarter 2009. The company reported a net loss of $3.8 million , for the second quarter of 2009, compared to a net loss of $2.8 million for the corresponding period in 2008.
